Kalydeco (ivacaftor) ahora aprobado en Canadá para niños de 1-2 años

The Canadian medicines regulatory body, Health Canada, has extended the approval of cystic fibrosis (CF) treatment, Kalydeco (ivacaftor). Already approved for children aged 6 and above, this medicine can now be used for children aged between 1 and 2 years old.

Kalydeco (ivacaftor) is a targeted therapy used for the treatment of CF patients with certain mutations. In this latest clinical trial, Kalydeco (ivacaftor) had a similar safety profile for children aged 1-2 as for older children in previous studies.

A new study in children younger than 24 months is currently underway to explore potential applications of Kalydeco (ivacaftor). Get more details on Cystic Fibrosis News Today.